Opinion|Videos|February 11, 2025
PALOMA-3: Managing AEs
Panelists discuss the safety and efficacy data from the phase 3 PALOMA-3 trial, and how they may lead to future considerations of the subcutaneous use of amivantamab with lazertinib in the front line.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
4
Carotuximab/Apalutamide Further Extends PFS in Metastatic CRPC
5